PDL BioPharma, Inc.
PDLI
PDLI was delisted on the 30th of December, 2020.
4 hedge funds and large institutions have $26.5K invested in PDL BioPharma, Inc. in 2023 Q1 according to their latest regulatory filings, with 1 funds opening new positions, increasing their positions, 1 reducing their positions, and closing their positions.
33% more funds holding
Funds holding: 3 → 4 (+1)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DT
Diversified Trust
Memphis,
Tennessee
|
+$26.5K |
Top Sellers
PDLI Hedge Fund Activity: Q1 2023 in Review
4 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in PDL BioPharma, Inc. (PDLI) for Q1 2023, worth a combined $26.5K.
Buyers outnumbered sellers: 1 fund opened new PDLI positions and 0 closed out — a net gain of 1 holder — while 0 added to existing stakes and 1 trimmed.
The largest buyer was Diversified Trust, opening a new position worth an estimated $26.5K.
- 4 institutional investors held PDL BioPharma, Inc. (PDLI) as of Q1 2023, up from 3 in Q4 2022.
- Funds reported $26.5K of PDL BioPharma, Inc. stock for Q1 2023.
- 1 fund opened new PDL BioPharma, Inc. positions in Q1 2023 and 0 closed out, a net change of +1 holder.
- The largest PDL BioPharma, Inc. buyer in Q1 2023 was Diversified Trust, an estimated $26.5K added.
Based on aggregated 13F filings for Q1 2023.